KCNJ16-depleted kidney organoids recapitulate tubulopathy and lipid recovery upon statins treatment.

E Sendino GarvíG J J van SlobbeE A ZaalJ H F de BaaijJ G HoenderopR MasereeuwM J JanssenA M van Genderen

Published in: Stem cell research & therapy (2024)

Mature kidney organoids represent a relevant in vitro model for investigating the function of Kir5.1. We discovered novel molecular targets for this genetic tubulopathy and identified statins as a potential therapeutic strategy for KCNJ16 defects in the kidney.

Keyphrases

cardiovascular disease
type diabetes
gene expression
dna methylation
replacement therapy